Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... The patient had progression of disease on IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine and developed HFS again, which was ...
2009 NOV 9 ... molecular-targeted therapy with anti-epidermal growth factor receptor (EGFR) antibody (cetuximab) for endometrial cancer to develop a new treatment for advanced endometrial cancer. We ...
2009 NOV 9 ... GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab. Patients with advanced K-RAS wild-type, colorectal cancer receiving irinotecan...
2009 NOV 9 ... "Mutation of the KRAS gene predicts the clinical response to the monoclonal antibody cetuximab in patients with advanced colorectal cancer (CRC). This study aimed to perform KRAS ...
2009 OCT 19 ... "Immunotherapy with the EGFR-specific mAb cetuximab is clinically effective in 10-20% of patients with squamous cell carcinoma of the head ...
2009 NOV 9 ... are lacking. We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash," scientists in the United States report. "In all, 24 ...
2009 NOV 2 ... Research findings, 'Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric ...
2009 OCT 19 ... Investigators publish new data in the report 'Combination treatment of Cetuximab and photodynamic therapy in SNU-1041 squamous cancer cell line.' According to recent ...
2009 NOV 23 ... Not all patients treated with trastuzumab (indication: breast cancer) and cetuximab (indication: metastatic colorectal cancer) respond well even when the patients are ...
2009 NOV 2 ... according to their epidermal growth factor receptor (EGFR) gene amplification status. Cetuximab was administered intravenously at a dose of 400 mg/m(2) on week 1 followed by weekly ...
2009 OCT 19 ... showed that patients with advanced colorectal cancer had improved overall survival when cetuximab, an epidermal growth factor receptor-targeting antibody, was given in addition to best ...
2009 NOV 9 ... "A phase III trial has shown the superiority of concurrent cetuximab and radiotherapy versus radiotherapy alone for the treatment of locally advanced head ...
2009 NOV 2 ... therapies targeted frontline involve cisplatin and gemcitabine with or without cetuximab (ongoing), and with or without bevacizumab (CALGB proposed trial). With the advent of ...
2009 NOV 2 ... investigators in Seoul, South Korea report. "As an adjuvant therapy, cetuximab (0.5 mg, two times) was intraperitoneally administered 4 weeks after nitrosourea ...
2009 NOV 9 ... day 1, plus 5-FU 1000 mg/m(2), days 1-5 (CF), either alone or in combination with cetuximab (CET-CF; 400 mg/m(2) initial dose followed by 250 mg/m(2) weekly thereafter). The ...
2009 NOV 2 ... According to recent research from the United States, "Cetuximab and panitumumab are chimeric and fully human monoclonal antibodies, respectively, ...
2009 NOV 9 ... compound effective in the treatment of colorectal cancer. Oxaliplatin combined with cetuximab for metastatic colorectal cancer is under evaluation." "The preliminary ...
2009 NOV 16 ... New investigation results, 'Nuclear EGFR contributes to acquired resistance to cetuximab,' are detailed in a study published in Oncogene. According to a study from the United ...
2009 NOV 16 ... nimotuzumab in the BEST trial was similar to that demonstrated in separate trials with cetuximab in locally advanced head and neck cancer but there was no evidence that nimotuzumab's ...
